Limits...
Treatment outcome of acute promyelocytic leukemia with modified aida protocol.

Pagnano KB, de Carvalho Duarte G, Lorand-Metze I, Delamain MT, Miranda EC, De Souza CA - Adv Hematol (2010)

Bottom Line: After a median follow up of 52 months, no molecular or hematological relapse has occurred.The 4-year disease-free survival is 82%.The study showed the antileukemic efficacy of mitoxantrone and that it could be used as a reasonable option in anthracycline-based strategies in APL.

View Article: PubMed Central - PubMed

Affiliation: Hematology and Hemotherapy Center, University of Campinas, SP, Rua Carlos Chagas 480, Campinas 13083-970, Brazil.

ABSTRACT
We analyzed the outcome of a series of 19 newly diagnosed patients with acute promyelocytic leukemia treated with AIDA modified protocol, using mitoxantrone in place of idarubicin. Eleven patients achieved morphologic CR (58%). The remaining 8 patients had induction failure due to death during induction. Ten of eleven patients in CR achieved molecular remission after induction therapy and all the 8 patients had molecular remission after consolidation. Eight patients completed the three consolidation courses as scheduled and then proceeded to maintenance therapy. After a median follow up of 52 months, no molecular or hematological relapse has occurred. The 4-year disease-free survival is 82%. The study showed the antileukemic efficacy of mitoxantrone and that it could be used as a reasonable option in anthracycline-based strategies in APL.

No MeSH data available.


Related in: MedlinePlus

Disease-free survival of APL patients.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2871550&req=5

fig1: Disease-free survival of APL patients.

Mentions: Between March 1999 and May 2006, 19 patients with APL were treated with the previously described AIDA modified protocol with mitoxantrone replacing idarubicin. The main clinical and biologic characteristics of the 19 patients are described in Table 1. Eleven patients achieved morphologic CR (58%). The remaining 8 patients had induction failure due to death during induction, 4 attributable to cerebral or pulmonary hemorrhage (50%), 3 to infection, and one to differentiation syndrome. Eight deaths occurred among the 10 patients with white blood cell count (WBC) at presentation greater than 2.7 × 109/L (median), while the remaining 3 deaths occurred among 9 patients with WBC less than 2.7 × 109/L (P = .01). Ten of 11 patients who achieved CR proceeded to consolidation therapy. One patient died from pulmonary Mycobacterium tuberculosis infection before consolidation. Two of 10 patients died during consolidation, one after the first cycle and one after the third cycle, both due to infection. The remaining 8 patients completed the three consolidation courses as scheduled, and then proceeded to maintenance therapy. One patient interrupted maintenance therapy due to a second episode of pancreatitis. Ten of eleven evaluable patients achieved molecular remission after induction therapy, and all the 8 patients had molecular remission after consolidation. After a median follow-up of 52 months, no molecular or hematological relapse has occurred. The 4-year disease-free survival is 82% (Figure 1) and the cumulative incidence of relapse was 0% in this population.


Treatment outcome of acute promyelocytic leukemia with modified aida protocol.

Pagnano KB, de Carvalho Duarte G, Lorand-Metze I, Delamain MT, Miranda EC, De Souza CA - Adv Hematol (2010)

Disease-free survival of APL patients.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2871550&req=5

fig1: Disease-free survival of APL patients.
Mentions: Between March 1999 and May 2006, 19 patients with APL were treated with the previously described AIDA modified protocol with mitoxantrone replacing idarubicin. The main clinical and biologic characteristics of the 19 patients are described in Table 1. Eleven patients achieved morphologic CR (58%). The remaining 8 patients had induction failure due to death during induction, 4 attributable to cerebral or pulmonary hemorrhage (50%), 3 to infection, and one to differentiation syndrome. Eight deaths occurred among the 10 patients with white blood cell count (WBC) at presentation greater than 2.7 × 109/L (median), while the remaining 3 deaths occurred among 9 patients with WBC less than 2.7 × 109/L (P = .01). Ten of 11 patients who achieved CR proceeded to consolidation therapy. One patient died from pulmonary Mycobacterium tuberculosis infection before consolidation. Two of 10 patients died during consolidation, one after the first cycle and one after the third cycle, both due to infection. The remaining 8 patients completed the three consolidation courses as scheduled, and then proceeded to maintenance therapy. One patient interrupted maintenance therapy due to a second episode of pancreatitis. Ten of eleven evaluable patients achieved molecular remission after induction therapy, and all the 8 patients had molecular remission after consolidation. After a median follow-up of 52 months, no molecular or hematological relapse has occurred. The 4-year disease-free survival is 82% (Figure 1) and the cumulative incidence of relapse was 0% in this population.

Bottom Line: After a median follow up of 52 months, no molecular or hematological relapse has occurred.The 4-year disease-free survival is 82%.The study showed the antileukemic efficacy of mitoxantrone and that it could be used as a reasonable option in anthracycline-based strategies in APL.

View Article: PubMed Central - PubMed

Affiliation: Hematology and Hemotherapy Center, University of Campinas, SP, Rua Carlos Chagas 480, Campinas 13083-970, Brazil.

ABSTRACT
We analyzed the outcome of a series of 19 newly diagnosed patients with acute promyelocytic leukemia treated with AIDA modified protocol, using mitoxantrone in place of idarubicin. Eleven patients achieved morphologic CR (58%). The remaining 8 patients had induction failure due to death during induction. Ten of eleven patients in CR achieved molecular remission after induction therapy and all the 8 patients had molecular remission after consolidation. Eight patients completed the three consolidation courses as scheduled and then proceeded to maintenance therapy. After a median follow up of 52 months, no molecular or hematological relapse has occurred. The 4-year disease-free survival is 82%. The study showed the antileukemic efficacy of mitoxantrone and that it could be used as a reasonable option in anthracycline-based strategies in APL.

No MeSH data available.


Related in: MedlinePlus